Senti Research Development vs Total Operating Expenses Analysis

SNTI Stock

USD 2.17 0.05 2.36%

Senti Biosciences financial indicator trend analysis is much more than just breaking down Senti Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Senti Biosciences is a good investment. Please check the relationship between Senti Biosciences Research Development and its Total Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Senti Biosciences Research Development account and Total Operating Expenses. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Senti Biosciences' Research Development and Total Operating Expenses is 0.98. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Senti Biosciences, assuming nothing else is changed. The correlation between historical values of Senti Biosciences' Research Development and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Senti Biosciences are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Research Development i.e., Senti Biosciences' Research Development and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Senti Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Senti Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.The current Selling General Administrative is estimated to decrease to about 25.5 M. The current Issuance Of Capital Stock is estimated to decrease to about 486.4 K

	2021	2022	2023	2024 (projected)
Total Operating Expenses	42.7M	74.9M	94.7M	53.9M
Cost Of Revenue	3.0M	3.9M	5.2M	6.8M

Total Operating Expenses Cost Of Revenue

Senti Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.97	0.97	0.44	0.74	0.99	-0.35	-0.85	0.33	0.9	0.99	0.82	0.63	0.95	0.5	-0.86	0.3	0.59	0.92	0.47	1.0	0.85	0.92	0.95	-0.96	-0.44
Other Current Liab	0.97		0.94	0.52	0.71	1.0	-0.36	-0.76	0.3	0.83	0.99	0.68	0.69	0.96	0.37	-0.74	0.48	0.47	0.84	0.36	0.96	0.78	0.85	0.89	-0.92	-0.44
Total Current Liabilities	0.97	0.94		0.26	0.63	0.94	-0.47	-0.84	0.54	0.95	0.95	0.83	0.7	0.94	0.48	-0.87	0.19	0.59	0.9	0.62	0.98	0.76	0.88	0.92	-0.91	-0.23
Total Stockholder Equity	0.44	0.52	0.26		0.8	0.54	0.53	-0.42	-0.54	0.03	0.52	0.04	-0.1	0.32	0.38	-0.06	0.58	0.37	0.19	-0.54	0.38	0.64	0.46	0.52	-0.57	-0.9
Net Tangible Assets	0.74	0.71	0.63	0.8		0.75	0.35	-0.87	-0.17	0.5	0.76	0.58	-0.02	0.57	0.81	-0.56	0.15	0.82	0.63	-0.01	0.73	0.9	0.78	0.86	-0.89	-0.82
Property Plant And Equipment Net	0.99	1.0	0.94	0.54	0.75		-0.32	-0.79	0.25	0.84	1.0	0.72	0.65	0.95	0.42	-0.78	0.45	0.51	0.87	0.35	0.97	0.82	0.88	0.92	-0.94	-0.5
Net Debt	-0.35	-0.36	-0.47	0.53	0.35	-0.32		-0.01	-0.69	-0.6	-0.31	-0.38	-0.88	-0.54	0.42	0.47	-0.17	0.31	-0.46	-0.72	-0.38	0.11	-0.14	-0.1	0.09	-0.53
Retained Earnings	-0.85	-0.76	-0.84	-0.42	-0.87	-0.79	-0.01		-0.29	-0.78	-0.82	-0.85	-0.2	-0.7	-0.87	0.82	0.14	-0.92	-0.82	-0.45	-0.87	-0.89	-0.89	-0.96	0.95	0.48
Accounts Payable	0.33	0.3	0.54	-0.54	-0.17	0.25	-0.69	-0.29		0.6	0.27	0.44	0.62	0.41	0.09	-0.44	-0.3	0.19	0.36	0.86	0.37	-0.03	0.23	0.25	-0.22	0.67
Cash	0.9	0.83	0.95	0.03	0.5	0.84	-0.6	-0.78	0.6		0.85	0.93	0.69	0.91	0.43	-0.96	0.01	0.54	0.96	0.8	0.93	0.63	0.77	0.82	-0.81	-0.09
Non Current Assets Total	0.99	0.99	0.95	0.52	0.76	1.0	-0.31	-0.82	0.27	0.85		0.75	0.63	0.94	0.46	-0.8	0.39	0.55	0.88	0.38	0.98	0.85	0.91	0.94	-0.96	-0.49
Non Currrent Assets Other	0.82	0.68	0.83	0.04	0.58	0.72	-0.38	-0.85	0.44	0.93	0.75		0.4	0.77	0.62	-0.99	-0.23	0.69	0.96	0.76	0.86	0.68	0.76	0.81	-0.8	-0.21
Other Assets	0.63	0.69	0.7	-0.1	-0.02	0.65	-0.88	-0.2	0.62	0.69	0.63	0.4		0.78	-0.28	-0.51	0.49	-0.15	0.57	0.56	0.62	0.19	0.41	0.39	-0.4	0.23
Cash And Short Term Investments	0.95	0.96	0.94	0.32	0.57	0.95	-0.54	-0.7	0.41	0.91	0.94	0.77	0.78		0.28	-0.83	0.4	0.38	0.9	0.54	0.95	0.65	0.75	0.81	-0.84	-0.28
Net Receivables	0.5	0.37	0.48	0.38	0.81	0.42	0.42	-0.87	0.09	0.43	0.46	0.62	-0.28	0.28		-0.53	-0.45	0.99	0.49	0.23	0.52	0.72	0.64	0.72	-0.7	-0.47
Common Stock Shares Outstanding	-0.86	-0.74	-0.87	-0.06	-0.56	-0.78	0.47	0.82	-0.44	-0.96	-0.8	-0.99	-0.51	-0.83	-0.53		0.11	-0.61	-0.98	-0.75	-0.89	-0.68	-0.77	-0.81	0.81	0.22
Short Term Investments	0.3	0.48	0.19	0.58	0.15	0.45	-0.17	0.14	-0.3	0.01	0.39	-0.23	0.49	0.4	-0.45	0.11		-0.4	0.07	-0.41	0.23	0.15	0.13	0.12	-0.18	-0.39
Other Current Assets	0.59	0.47	0.59	0.37	0.82	0.51	0.31	-0.92	0.19	0.54	0.55	0.69	-0.15	0.38	0.99	-0.61	-0.4		0.57	0.32	0.61	0.76	0.71	0.78	-0.77	-0.43
Other Stockholder Equity	0.92	0.84	0.9	0.19	0.63	0.87	-0.46	-0.82	0.36	0.96	0.88	0.96	0.57	0.9	0.49	-0.98	0.07	0.57		0.66	0.94	0.74	0.81	0.86	-0.86	-0.32
Total Liab	0.47	0.36	0.62	-0.54	-0.01	0.35	-0.72	-0.45	0.86	0.8	0.38	0.76	0.56	0.54	0.23	-0.75	-0.41	0.32	0.66		0.53	0.13	0.34	0.38	-0.36	0.47
Total Current Assets	1.0	0.96	0.98	0.38	0.73	0.97	-0.38	-0.87	0.37	0.93	0.98	0.86	0.62	0.95	0.52	-0.89	0.23	0.61	0.94	0.53		0.84	0.92	0.95	-0.95	-0.4
Common Stock	0.85	0.78	0.76	0.64	0.9	0.82	0.11	-0.89	-0.03	0.63	0.85	0.68	0.19	0.65	0.72	-0.68	0.15	0.76	0.74	0.13	0.84		0.96	0.95	-0.93	-0.73
Property Plant Equipment	0.92	0.85	0.88	0.46	0.78	0.88	-0.14	-0.89	0.23	0.77	0.91	0.76	0.41	0.75	0.64	-0.77	0.13	0.71	0.81	0.34	0.92	0.96		0.97	-0.94	-0.53
Short Long Term Debt Total	0.95	0.89	0.92	0.52	0.86	0.92	-0.1	-0.96	0.25	0.82	0.94	0.81	0.39	0.81	0.72	-0.81	0.12	0.78	0.86	0.38	0.95	0.95	0.97		-0.99	-0.55
Current Deferred Revenue	-0.96	-0.92	-0.91	-0.57	-0.89	-0.94	0.09	0.95	-0.22	-0.81	-0.96	-0.8	-0.4	-0.84	-0.7	0.81	-0.18	-0.77	-0.86	-0.36	-0.95	-0.93	-0.94	-0.99		0.58
Non Current Liabilities Total	-0.44	-0.44	-0.23	-0.9	-0.82	-0.5	-0.53	0.48	0.67	-0.09	-0.49	-0.21	0.23	-0.28	-0.47	0.22	-0.39	-0.43	-0.32	0.47	-0.4	-0.73	-0.53	-0.55	0.58

Click cells to compare fundamentals

Senti Biosciences Account Relationship Matchups

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:

How To Invest In Senti

Details

Is Senti Stock a good investment?

Details

What is Senti Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(15.59)

Revenue Per Share

0.075

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.33)

Return On Equity

(1.11)

The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Senti Research Development vs Total Operating Expenses Analysis

Research Development vs Total Operating Expenses

Research Development vs Total Operating Expenses Correlation Analysis

Correlation Coefficient

Research Development

Total Operating Expenses

Senti Biosciences fundamental ratios Correlations

Senti Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Other Current Liab
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Net	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Other Current Liab

Current Deferred Revenue	- 0.99	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.99	Non Currrent Assets Other
Other Stockholder Equity	- 0.98	Common Stock Shares Outstanding
Current Deferred Revenue	- 0.96	Non Current Assets Total
Common Stock Shares Outstanding	- 0.96	Cash
Short Long Term Debt Total	- 0.96	Retained Earnings